These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 29695963)
1. The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice. Schafer C; Moore V; Dasgupta N; Javadov S; James JF; Glukhov AI; Strauss AW; Khuchua Z Front Pharmacol; 2018; 9():318. PubMed ID: 29695963 [No Abstract] [Full Text] [Related]
2. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226 [TBL] [Abstract][Full Text] [Related]
3. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation. Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899 [TBL] [Abstract][Full Text] [Related]
4. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome. Soustek MS; Baligand C; Falk DJ; Walter GA; Lewin AS; Byrne BJ J Inherit Metab Dis; 2015 Sep; 38(5):915-22. PubMed ID: 25860817 [TBL] [Abstract][Full Text] [Related]
5. Stimulating myocardial pyruvate dehydrogenase activity fails to alleviate cardiac abnormalities in a mouse model of human Barth syndrome. Greenwell AA; Tabatabaei Dakhili SA; Gopal K; Saed CT; Chan JSF; Kazungu Mugabo N; Zhabyeyev P; Eaton F; Kruger J; Oudit GY; Ussher JR Front Cardiovasc Med; 2022; 9():997352. PubMed ID: 36211560 [TBL] [Abstract][Full Text] [Related]
6. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction. Phoon CK; Acehan D; Schlame M; Stokes DL; Edelman-Novemsky I; Yu D; Xu Y; Viswanathan N; Ren M J Am Heart Assoc; 2012 Apr; 1(2):. PubMed ID: 23130124 [TBL] [Abstract][Full Text] [Related]
7. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome. Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435 [TBL] [Abstract][Full Text] [Related]
8. A critical appraisal of the tafazzin knockdown mouse model of Barth syndrome: what have we learned about pathogenesis and potential treatments? Ren M; Miller PC; Schlame M; Phoon CKL Am J Physiol Heart Circ Physiol; 2019 Dec; 317(6):H1183-H1193. PubMed ID: 31603701 [TBL] [Abstract][Full Text] [Related]
9. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430 [TBL] [Abstract][Full Text] [Related]
11. The Influence of Supplemental Dietary Linoleic Acid on Skeletal Muscle Contractile Function in a Rodent Model of Barth Syndrome. Elkes M; Andonovski M; Vidal D; Farago M; Modafferi R; Claypool SM; LeBlanc PJ Front Physiol; 2021; 12():731961. PubMed ID: 34489741 [TBL] [Abstract][Full Text] [Related]
12. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. Soustek MS; Falk DJ; Mah CS; Toth MJ; Schlame M; Lewin AS; Byrne BJ Hum Gene Ther; 2011 Jul; 22(7):865-71. PubMed ID: 21091282 [TBL] [Abstract][Full Text] [Related]